We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » INDIAN GENERIC FIRMS RISING ON COST, API COMPETITIVE ADVANTAGES
INDIAN GENERIC FIRMS RISING ON COST, API COMPETITIVE ADVANTAGES
March 12, 2004
In the global race to capture the more than $40 billion worth of brand drugs going off patent over the next few years, India’s generic drugmakers are emerging as significant competitors, according to experts.